Home・Aktien・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

2.37 -3.27

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.37

Max

2.48

Schlüsselkennzahlen
By Trading Economics
Einkommen	14M -1M
Verkäufe	16M 21M
EPS	-0.003
Gewinnspanne	-4.943
Angestellte	81
EBITDA	15M 657K

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+103.64% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	324M 1B
Vorheriger Eröffnungskurs	5.64
Vorheriger Schlusskurs	2.37

Nachrichtenstimmung

By Acuity

51%

49%

245 / 340 Ranking in Healthcare

Lexicon Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Aug. 2026, 19:56 UTC

News

Lexicon Pharmaceuticals reported a second-quarter earnings loss of -$0.06 per share, missing expectations. Shares are lower amid a downgrade to “sell” from Wall Street Zen.

7. Aug. 2026, 22:01 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market hours, continuing a notable decline since Friday's close, with no specific news identified to explain the movement.

6. Aug. 2026, 23:26 UTC

Lexicon Pharmaceuticals shares are trading higher in after-market hours, following three consecutive sessions of declines. No specific news was identified for the price movement.

5. Aug. 2026, 19:36 UTC

News

Lexicon Pharmaceuticals Inc shares are lower as investors adjust positions ahead of Q2 earnings on August 5, with consensus EPS estimates at -$0.05.

4. Aug. 2026, 19:56 UTC

Lexicon Pharmaceuticals shares are higher today, reflecting strong momentum amid easing inflation concerns from declining crude oil prices. No specific news was identified.

31. Juli 2026, 19:46 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reflecting broader market trends amid rising yields and crude oil prices contributing to inflation concerns.

30. Juli 2026, 23:11 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market hours. The decline follows broader market uncertainty after the Federal Reserve's interest rate decision.

29. Juli 2026, 21:02 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market declines amid rising oil prices and geopolitical tensions in the Middle East.

27. Juli 2026, 19:03 UTC

Lexicon Pharmaceuticals Inc is trading lower today, breaking a trend of higher daily closes. Broader market declines and falling oil prices may influence sentiment.

24. Juli 2026, 20:07 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reversing from earlier gains amid broader market volatility influenced by falling oil prices and inflation concerns.

22. Juli 2026, 19:02 UTC

Lexicon Pharmaceuticals Inc shares are lower today, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

21. Juli 2026, 19:42 UTC

Lexicon Pharmaceuticals is higher as the market gains momentum, driven by strong performances from major companies and a resurgence in semiconductor stocks.

20. Juli 2026, 19:06 UTC

Lexicon Pharmaceuticals Inc shares are lower today, following three days of gains. Broader market declines are linked to rising US Treasury yields and oil prices above $90.

Peer-Vergleich

Kursveränderung

Lexicon Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

103.64% Vorteil

12-Monats-Prognose

Durchschnitt 5.03 USD 103.64%

Hoch 6 USD

Tief 3.1 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lexicon Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lexicon Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

245 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.